IBRX - Immunitybio Inc logo

Immunitybio Inc

IBRX
Rev 3768xtop 1%10Y
Compare IBRX Hold

ImmunityBio, Inc. develops next-generation immunotherapies to activate the immune system against cancer and infectious diseases. Its primary revenue source is the FDA-approved immunotherapy Anktiva for treating BCG-unresponsive non-muscle invasive bladder cancer.

βš•οΈ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago β†’$1,240today

Score Overview

1 Year
Score
Net Growth-182.40%
Net TrendShrank
Net Income Consistencyβ€”
Rev Growth46.35%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score4.3
Net Growth-186.16%
Net Trend40%
Net Income Consistencyβ€”
Rev Growth177x
Rev Trend80%
Revenue Consistencyβ€”
10 Years
Score
Net Growth-6x
Net Trend50%
Net Income Consistency
Rev Growth3768x
Rev Trend80%
Revenue Consistency
All Time
Score
Net Growth-318.94%
Net Trend55%
Net Income Consistency
Rev Growth702x
Rev Trend73%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Immunitybio Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. IBRX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-23
$ 8.22β€”
1 Year2025-10-23
$ 2.39243.93%
5 Years2021-10-22
$ 8.27-0.60%
10 Years2016-10-21
$ 6.6323.98%
All Time2015-07-28
$ 34.64-76.27%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 165M-$ 992M$ 357M
2025$ 113M-$ 351M$ 242M
2024$ 14M-$ 413M$ 149M
2023$ 622K-$ 583M$ 266M
2022$ 240K-$ 416M$ 107M
2021$ 934K-$ 346M$ 317M
2020$ 605K-$ 221M$ 96M
2019$ 43K-$ 65M$ 51M
2018$ 47K-$ 96M$ 74M
2017$ 45K-$ 96M$ 128M
2016$ 44K-$ 120M$ 198M
IPO2015$ 236K-$ 236M$ 294M
IBRX - Immunitybio Inc logo

Immunitybio Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 605K to $ 113M and net income went from -$ 221M to -$ 351M. Revenue increased in 4 of those 5 years; net income in 2.

Across Immunitybio Inc's full reported history, from 2015 to 2025, revenue grew from $ 236K to $ 113M and net income went from -$ 236M to -$ 351M. Revenue increased in 73% of the years measured; net income in 55%.

Immunitybio Inc currently holds a 5-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.

Membership

Explore IBRX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,112 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year Β· Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies